Summary
EudraCT Number: 2007-007758-70
Sponsor's Protocol Code Number: NH19707
National Competent Authority: Spain - AEMPS 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2008-06-02
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007758-70/ES/

A. Protocol Information
A.1 Member State Concerned: Spain - AEMPS
A.2 EudraCT number: 2007-007758-70
A.3 Full title of the trial: Estudio multicéntrico, abierto, de dosis múltiples, para determinar la dosis inicial óptima de MIRCERA® administrada por vía intravenosa para el tratamiento de mantenimiento de la anemia en pacientes pediátricos con enfermedad renal crónica en Hemodiálisis
A.4.1 Sponsor's protocol code number: NH19707
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: F. Hoffmann-La Roche Ltd
B.1.3.4	Country: Switzerland
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: MIRCERA®
D.2.1.1.2 Name of the Marketing Authorisation holder: Roche Registration Ltd.
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Solution for injection
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: methoxy polyethylene glycol-epoetin beta
D.3.9.1 CAS number: 677324-53-7
D.3.9.2 Current sponsor code: RO0503821
D.3.10 Strength
D.3.10.1 Concentration unit: µg/ml microgram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 50/ to 1
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 2
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: MIRCERA®
D.2.1.1.2 Name of the Marketing Authorisation holder: Roche Registration Ltd.
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Solution for injection
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: methoxy polyethylene glycol-epoetin beta
D.3.9.1 CAS number: 677324-53-7
D.3.9.2 Current sponsor code: RO0503821
D.3.10 Strength
D.3.10.1 Concentration unit: µg/ml microgram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 100/ to 1
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 3
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: MIRCERA®
D.2.1.1.2 Name of the Marketing Authorisation holder: Roche Registration Ltd.
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Solution for injection
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: methoxy polyethylene glycol-epoetin beta
D.3.9.1 CAS number: 677324-53-7
D.3.9.2 Current sponsor code: RO0503821
D.3.10 Strength
D.3.10.1 Concentration unit: µg/ml microgram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 200/ to 1
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 4
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: MIRCERA®
D.2.1.1.2 Name of the Marketing Authorisation holder: Roche Registration Ltd.
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Solution for injection
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: methoxy polyethylene glycol-epoetin beta
D.3.9.1 CAS number: 677324-53-7
D.3.9.2 Current sponsor code: RO0503821
D.3.10 Strength
D.3.10.1 Concentration unit: µg/ml microgram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 400/ to 1
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Anemia asociada a enfermedad renal crónica en pacientes pediátricos sometidos a hemodiálisis 
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 9.1
E.1.2 Level: LLT
E.1.2 Classification code: 10058124
E.1.2 Term: Nephrogenic anemia
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: – Determinar la dosis inicial de MIRCERA® en pacientes pediátricos con ERC en hemodiálisis, que hayan sido tratados previamente durante una fase de mantenimiento de manera estable con epoetina alfa, epoetina beta o darbepoetina alfa.
–Demostrar las variaciones en las concentraciones de Hb en el transcurso del tiempo en respuesta a diferentes dosis iv de MIRCERA®

E.2.2 Secondary objectives of the trial: – Determinar la farmacocinética (PK) de MIRCERA® en pacientes pediátricos
– Investigar la relación entre la exposición y la respuesta de MIRCERA®
– Evaluar la seguridad y tolerancia de dosis múltiples de MIRCERA® en pacientes pediátricos
– Documentar la seguridad y eficacia a largo plazo de la administración de MIRCERA® en pacientes pediátricos con anemia asociada a ERC

E.2.3 Trial contains a sub-study: No
E.3 Principal inclusion criteria: 1. Consentimiento informado por escrito
2. Pacientes pediátricos de edades comprendidas entre 5 y 17 años, con anemia renal crónica clínicamente estable
3. El tratamiento con hemodiálisis se debe haber iniciado 8 semanas antes, como mínimo
4. Peso corporal > ó =10 kg
5. Hemodiálisis adecuada: URR >65% o Kt/V >1,2 en los pacientes que reciban HD tres veces por semana. Los pacientes que reciban más o menos sesiones de HD a la semana deben presentar un Kt/V semanal > ó =3,6
6. Concentración de Hb basal pre-diálisis entre 10,0 y 12,0 g/dl, determinada a partir de la media de los valores semanales de Hb obtenidos entre las semanas –2 a –1
7. Tratamiento de mantenimiento con epoetina alfa, epoetina beta o darbepoetina alfa por vía intravenosa, utilizando el mismo intervalo de administración como mínimo durante las 8 semanas previas a la visita de selección
8. Tratamiento de mantenimiento estable con epoetina alfa, epoetina beta o darbepoetina alfa, sin haber variado la dosis semanal > ó = 25% (incremento o reducción) durante las 2 semanas de screening. Los pacientes que hayan sido tratados previamente por vía sc podrán participar únicamente si se les han administrado los AEE por vía iv como mínimo 8 semanas antes del periodo de screening.
9. Estado de hierro adecuado: Definido por una concentración de ferritina sérica > ó =100 ng/ml o TSAT > ó =20% (o porcentaje de hematíes hipocrómicos <10%) de la media entre los dos valores determinados durante screening

E.4 Principal exclusion criteria: 1. Hemorragia gastrointestinal manifiesta en 8 semanas previas al período de selección o durante dicho período
2. Transfusiones de hematíes durante las 8 semanas previas al período de selección o durante dicho período
3. Hemoglobinopatías (p. ej. anemia drepanocítica homocigótica, cualquier tipo de talasemia)
4. Hemólisis
5. Enfermedad maligna activa
6. Enfermedad inflamatoria crónica, no controlada o sintomática (p. ej. lupus eritematoso sistémico)
7. Hipertensión mal controlada (p. ej. PA  percentil >95 para la edad y el sexo en dos sesiones de hemodiálisis consecutivas), a pesar de que la ultrafiltración sea adecuada
8. Ataques epilépticos en los 3 meses previos al período de selección y durante este período
9. Administración de cualquier fármaco en investigación en las 4 semanas previas al período de selección o que esté previsto durante el estudio
10. Hiperparatiroidismo severo (PTH intacta > ó = 1000 pg/ml o PTH entera > ó = 500 pg/ml) o fibrosis de médula ósea demostrada con biopsia
11. Hipersensibilidad confirmada a eritropoyetina recombinante humana, polietilenglicol o cualquier componente de la formulación del fármaco del estudio
12. Aplasia eritrocítica pura (PRCA) o antecedentes de PRCA
13. Probabilidad alta de retirada prematura o interrupción del estudio (p. ej. si está previsto que el paciente reciba un trasplante renal de un donante vivo en las 16 semanas siguientes a la randomización)
14. Cirugía programada durante todo el período de estudio (excepto la realizada para practicar el acceso para la hemodiálisis)

E.5 End points
E.5.1 Primary end point(s): La variable principal de este estudio será la variación producida en la concentración de Hb (g/dl) entre los períodos basal y de evaluación. Los diferentes grupos de dosis de MIRCERA® se compararán de manera exploratoria, utilizando estadística resumida basada en las medias, desviaciones estándar y percentiles. El análisis se realizará en todos los pacientes de los grupos de dosis combinados, al igual que se estratificará de acuerdo con el grupo de edad al que pertenezcan (> ó = 5 a <12 años frente a > ó =12 años).
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: Yes
E.6.7 Pharmacodynamic: Yes
E.6.8 Bioequivalence: No
E.6.9 Dose response: Yes
E.6.10 Pharmacogenetic: No
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: Information not present in EudraCT
E.7.1.2 Bioequivalence study: Information not present in EudraCT
E.7.1.3 Other: Information not present in EudraCT
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): Yes
E.7.3 Therapeutic confirmatory (Phase III): No
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: No
E.8.1.1 Randomised: Information not present in EudraCT
E.8.1.2 Open: Information not present in EudraCT
E.8.1.3 Single blind: Information not present in EudraCT
E.8.1.4 Double blind: Information not present in EudraCT
E.8.1.5 Parallel group: Information not present in EudraCT
E.8.1.6 Cross over: Information not present in EudraCT
E.8.1.7 Other: Information not present in EudraCT
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): Information not present in EudraCT
E.8.2.2 Placebo: Information not present in EudraCT
E.8.2.3 Other: Information not present in EudraCT
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.4.1 Number of sites anticipated in Member State concerned: 4
E.8.5 The trial involves multiple Member States: Yes
E.8.5.1 Number of sites anticipated in the EEA: 20
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: Yes
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned:
E.8.7 Trial has a data monitoring committee: Yes
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: 
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 
E.8.9.1 In the Member State concerned months: 5
E.8.9.1 In the Member State concerned days: 
E.8.9.2 In all countries concerned by the trial months: 5

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: Yes
F.1.1.1 In Utero: No
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): No
F.1.1.3 Newborns (0-27 days): No
F.1.1.4 Infants and toddlers (28 days-23 months): No
F.1.1.5 Children (2-11years): Yes
F.1.1.6 Adolescents (12-17 years): Yes
F.1.2 Adults (18-64 years): No
F.1.3 Elderly (>=65 years): No
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Yes
F.3.3.1 Women of childbearing potential not using contraception : No
F.3.3.2 Women of child-bearing potential using contraception: No
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: Yes
F.3.3.6.1 Details of subjects incapable of giving consent: Población pediátrica
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 5
F.4.2 For a multinational trial
F.4.2.2 In the whole clinical trial: 41

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2008-07-22
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2008-07-08

P. End of Trial
P. End of Trial Status: Completed
P. Date of the global end of the trial: 2016-03-29

